Back to Search
MARC THEORET, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1821322850Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
D63149(MD)
Research & Publications (13)
Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
PMID 17645835·Clin Genitourin Cancer·2007
3-trial
TSCOT+ thymic epithelial cell-mediated sensitive CD4 tolerance by direct presentation.
PMID 18684012·PLoS Biol·2008
7-preclinical
CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.
PMID 16882704·Blood·2006
7-preclinical
Cross-priming utilizes antigen not available to the direct presentation pathway.
PMID 16764686·Immunology·2006
7-preclinical
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.
PMID 16621986·J Immunol·2006
7-preclinical
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.
PMID 15931392·J Clin Invest·2005
7-preclinical
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
PMID 15585842·J Immunol·2004
4-observational
Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance.
PMID 15314692·J Clin Invest·2004
7-preclinical
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
PMID 14762166·Proc Natl Acad Sci U S A·2004
7-preclinical
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
PMID 12960359·J Immunol·2003
7-preclinical
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
PMID 12925674·J Exp Med·2003
7-preclinical
The future of interleukin-2: enhancing therapeutic anticancer vaccines.
PMID 10685664·Cancer J Sci Am·2000
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 10 CENTER DR, BUILDING 10CRC, ROOM 3-3888
BETHESDA, MD 20892 - Phone
- (301) 451-6955
Quick Facts
- NPI
- 1821322850
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 13
Are you this provider?
Claim Your Profile